Morepen Starts ₹825 Cr CDMO Supplies; ₹50 Cr Dispatch Completed in Q1FY26-27
Morepen Laboratories has begun commercial supplies for its ₹825 crore CDMO mandate, completing the first dispatch of ₹50 crore in Q1FY2026-27. The company expects to supply an additional ₹225 crore in Q2FY2026-27. Reactor capacity is set to reach 600 KL by end-Q2, expanding to 1,000 KL later.
The commencement of commercial supplies under a large ₹825 crore mandate and the planned significant expansion of manufacturing capacity are material developments that are likely to have a substantial impact on the company's future revenue and market position.
The company has successfully commenced commercial supplies under a significant CDMO mandate and is projecting further growth in supplies and manufacturing capacity, indicating positive business development.
Morepen Laboratories Limited has commenced commercial supplies under its ₹825 crore CDMO (Contract Development and Manufacturing Organization) mandate. The first commercial dispatch, valued at approximately ₹50 crore, was completed in Q1FY2026-27, marking the transition from validation to commercial execution.
Mr. Sanjay Suri, Managing Director, stated that this is a significant milestone in Morepen's strategy to establish long-duration global manufacturing partnerships. The company is focused on scaling up, expanding capacity, and building a stronger CDMO platform.
Morepen anticipates additional supplies of approximately ₹225 crore during Q2FY2026-27, contingent on customer schedules and regulatory requirements. To support its growing CDMO business, the company plans to increase its total reactor capacity to around 600 KL by the end of Q2, with further expansions to 800 KL and 1,000 KL in subsequent phases.
This development reinforces Morepen's strategic objective of building a scalable CDMO platform, fostering deeper customer relationships, and participating in global manufacturing opportunities.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under new orders. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.